Clinical trials: Relapsed
Multiple Sclerosis - Relapsing Remitting, Clinically Isolated Syndrome, CNS Demyelinating
DTI in Children With Multiple Sclerosis
This is a prospective, non-randomised, non-blinded, single center study of children and adolescents with multiple sclerosis and clinically isolated syndrome to detect differences or early changes in diffusion-weighted imaging…
- Trial name
- NCT02361697
- Testing
- DTI-MRI
- Where
- Germany
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University Hospital Muenster
Anaplastic Large Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma
17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin's Lymphoma
This phase II trial is studying how well 17-AAG works in treating patients with relapsed or refractory anaplastic large cell lymphoma, mantle cell lymphoma, or Hodgkin's lymphoma.
- Conditions
- Anaplastic Large Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Mantle Cell Lymphoma
- Trial name
- NCT00117988
- Testing
- tanespimycin
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- National Cancer Institute (NCI)
Purpura, Idiopathic Thrombocytopenic Purpura
Recombinant Human Thrombopoietin in Combination With Rituximab in Immune Thrombocytopenia (ITP)
The purpose of this study is to determine whether Recombinant Human Thrombopoietin (rh-TPO) in combination with Rituximab are effective and safe in the management of Steroid-Resistant/Relapsed Immune Thrombocytopenia (ITP).
- Trial name
- NCT01506414
- Testing
- rhTPO in combination with Rituximab
- Where
- China
- Volunteers
- 91 people
- Sponsor
- Ming Hou
Lymphoma
Fludarabine Phosphate, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed Hodgkin Lymphoma
RATIONALE: Giving chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells.
- Trial name
- NCT00907036
- Testing
- alemtuzumab, donor lymphocytes, cyclosporine
- Volunteers
- 49 people
- Sponsor
- Cancer Research UK
Myelodysplastic Syndromes, de Novo, Myelodysplastic Syndromes, Secondary
Venetoclax Basket Trial for High Risk Hematologic Malignancies
This trial is evaluating the safety and tolerability of venetoclax with chemotherapy in pediatric and young adult patients with hematologic malignancies, including myelodysplastic syndrome (MDS), acute myeloid leukemia derived…
- Conditions
- Myelodysplastic Syndromes, de Novo, Myelodysplastic Syndromes, Secondary, Myelodysplastic Syndromes, Previously Treated, Treatment-Related Acute Myeloid Leukemia
- Trial name
- NCT05292664
- Testing
- Venetoclax, Azacitidine, Cytarabine
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- Andrew E. Place, MD
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
G-CSF-Treated Donor Bone Marrow Transplant in Treating Patients With Hematologic Disorders
RATIONALE: Giving chemotherapy drugs and total-body irradiation before a donor bone marrow transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem…
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00253552
- Testing
- filgrastim, busulfan, cyclophosphamide
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- OHSU Knight Cancer Institute
Unspecified Childhood Solid Tumor, Protocol Specific
Aflibercept in Treating Young Patients With Relapsed or Refractory Solid Tumors
This phase I trial is studying the side effects and best dose of aflibercept in treating young patients with relapsed or refractory solid tumors. Aflibercept may stop the growth of tumor cells by blocking blood flow to the tumor.
- Trial name
- NCT00622414
- Testing
- ziv-aflibercept
- Where
- 6 sites in United States
- Volunteers
- 27 people
- Sponsor
- National Cancer Institute (NCI)
Medulloblastoma, Central Nervous System Tumors
Clinical Studies of Gemcitabine-Oxaliplatin
These are Phase 2 single-arm studies of gemcitabine in combination with oxaliplatin in refractory or relapsing pediatric solid tumors.
- Conditions
- Medulloblastoma, Central Nervous System Tumors, Neuroblastoma, Osteosarcoma
- Trial name
- NCT00407433
- Testing
- Gemcitabine (Gemzar®), Oxaliplatin (Eloxatin®)
- Where
- France
- Volunteers
- 156 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Recurrent Childhood Acute Lymphoblastic Leukemia
Alemtuzumab With or Without Methotrexate and Mercaptopurine in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia
This phase II trial is studying how well giving alemtuzumab with or without methotrexate and mercaptopurine works in treating young patients with relapsed acute lymphoblastic leukemia.
- Trial name
- NCT00089349
- Testing
- alemtuzumab, methotrexate, mercaptopurine
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)
Inflammatory Bowel Diseases (IBD), Crohn's Disease (CD)
Fecal Microbiota Transplantation in Pediatric Patients
A disturbance in the diversity of gut bacterial composition could be linked to several immune mediated diseases including inflammatory bowel diseases (IBD).
- Conditions
- Inflammatory Bowel Diseases (IBD), Crohn's Disease (CD), Ulcerative Colitis (UC)
- Trial name
- FMT (NCT02108821)
- Testing
- Fecal Microbiota Transplantation (FMT)
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Children's Mercy Hospital Kansas City
Leukemia
Efficiency Study of Low Dose of IL-2 to Prevent Relapse in Standard Risk Leukemia After Transplantation
Hematopoietic stem cell transplantation (HSCT) is one of the best, and sometimes the only, option for the treatment of leukemia.
- Trial name
- NCT01517347
- Testing
- Interleukin-2
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Peking University People's Hospital
B Cell Lymphoma, Acute Lymphoblastic Leukemia
Anti-CD22 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy for Relapsed Refractory B-cell Malignancies
This is a single-center, open-label, single-arm study to evaluate the safety and efficacy of anti-CD22 CAR-T cells in patients with relapsed or refractory B-cell Malignancies.
- Trial name
- NCT04007978
- Testing
- Third generation CAR-T cells
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Osteosarcoma, Osteosarcoma in Children
Effects of Maintenance Cabozantinib+BSC Versus BSC in Children and AYA With Osteosarcoma
The participants of this study will be children, adolescents, and young adults with residual osteosarcoma, which cannot be removed completely through surgery.
- Conditions
- Osteosarcoma, Osteosarcoma in Children, Osteosarcoma in Adolescents and Young Adults
- Trial name
- CabOSTar (NCT06341712)
- Testing
- Cabozantinib, Best Supportive Care (BSC)
- Where
- 16 sites in United States, Belgium and 8 more
- Volunteers
- 10 people
- Sponsor
- Ipsen
Disseminated Neuroblastoma, Recurrent Neuroblastoma
ABT-751 in Treating Children With Neuroblastoma That Has Relapsed or Not Responded to Previous Treatment
This phase II trial is studying how well ABT-751 works in treating children with neuroblastoma that has relapsed or not responded to previous treatment.
- Trial name
- NCT00436852
- Testing
- ABT-751, quality-of-life assessment
- Where
- 12 sites in United States, Canada
- Volunteers
- 92 people
- Sponsor
- Children's Oncology Group
Refractory Immune-mediated Platelet Transfusion Refractoriness, Relapsed or Refractory Immune Thrombocytopenia
RN1201 Injection in the Treatment of Antibody-Mediated Diseases
This single-arm, open-label exploratory trial aims to evaluate the safety, feasibility, and preliminary efficacy of RN1201 Injection in patients with antibody-mediated diseases, including refractory immune-mediated platelet…
- Trial name
- NCT07072247
- Testing
- CD19 and BCMA-targeted allogeneic CAR-T cells
- Where
- China
- Volunteers
- 9 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Diffuse Large B-Cell Lymphoma Refractory
Lenalidomide Plus ICE in the Treatment of Refractory and Relapsed DLBCL
This study is to evaluate the efficacy and safety of Lenalidomide plus ICE in the treatment of Refractory and Relapsed DLBCL patients.
- Trial name
- NCT03367143
- Testing
- Lenalidomide, Ifosfamide, Carboplatin
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Ruijin Hospital
Neuroblastoma
Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma
The purpose of this study is to find out if an antibody called Humanized 3F8 (Hu3F8) combined with granulocyte- macrophage colony stimulating factor (GM-CSF) is safe for treating neuroblastoma.
- Trial name
- NCT01757626
- Testing
- Hu3F8 With GM-CSF
- Where
- United States
- Volunteers
- 186 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Effect of Drug, Toxicity, Drug
Apatinib Plus IE Chemotherapy (Ifosfamide and Etoposide) for Relapsed or Refractory Osteosarcoma
Apatinib has led to positive responses in the treatment of osteosarcoma refractory to first-line chemotherapy. However, apatinib demonstrates only short-lived activity, and the disease control of musculoskeletal lesions is worse…
- Trial name
- AIEO (NCT04824352)
- Testing
- apatinib
- Where
- 2 sites in China
- Volunteers
- 44 people
- Sponsor
- Peking University People's Hospital
Leukemia
Yttrium Y 90 Anti-CD19 Antibody BU-12 in Patients With Advanced Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Lymphocytic Leukemia
RATIONALE: Radiolabeled monoclonal antibodies can find cancer cells and carry cancer-killing substances to them without harming normal cells. This may be effective treatment for leukemia.
- Trial name
- NCT00643240
- Testing
- yttrium Y 90 anti-CD19 monoclonal antibody BU12, 111In-BU-12
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
T Lymphoblastic Leukemia/Lymphoma, Mixed Phenotype Acute Leukemia
Humanized CD7 CAR T-cell Therapy for r/r CD7+ Acute Leukemia
This is a prospective,open-label, single center and single arm phase 1/2 study to evaluate the efficacy and safety of T cells expressing humanized CD7 chimeric antigen receptors treatment for patients with refractory/relapsed CD7…
- Conditions
- T Lymphoblastic Leukemia/Lymphoma, Mixed Phenotype Acute Leukemia, Acute Myeloid Leukemia
- Trial name
- NCT04762485
- Testing
- Humanized CD7 CAR-T cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The First Affiliated Hospital of Soochow University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.